search
Back to results

Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-398
CKD-501, D745
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

19 Years - 54 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy adults age≥19 years and age<55 years at the time of screening
  2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg

    * BMI = Weight(kg)/ Height(m)2

  3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
  4. Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital signs, ECG etc. performed at screening
  5. Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product
  6. Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion
  7. Individuals with the ability and willingness to participate the entire study period

Exclusion Criteria:

  1. Individuals with a medical evidence or a history (excluding a dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune diseases.
  2. Individuals with a medical history of gastrointestinal disease (e.g., gullet disease such as esophageal achalasia and esophagostenosis and Crohn's disease) or operations (excluding simple appendectomy, herniotomy or tooth extraction) that may affect drug absorption.
  3. Individuals with the following laboratory test results at screening:

    • ALT or AST > 2x the upper limit of the normal range

  4. History of regular alcohol consumption exceeding 210 g/week within the 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)
  5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening
  6. Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within the 6 months prior to the first dose of this study
  7. Following vital signs results at screening

    - Sitting systolic blood pressure ≥ 140 mmHg or < 90 mmHg and/or sitting diastolic blood pressure ≥90 mmHg or <60 mmHg

  8. Individuals with a medical history of significant alcohol or drug abuse within one year prior to the screening
  9. Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s)
  10. Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)
  11. Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)
  12. Individuals with severe acute/chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product(s) administration, or may interfere with the interpretation of study results
  13. Individuals with hypersensitivity to investigational products or the investigational products ingredients or dihydropyridine drugs
  14. Subject had severe heart failure(NYHA class 1, 2, 3, 4)
  15. Patients with hepatopathy
  16. Patients with diabetic ketogenic acidosis, diabetic comas and ex-coma, type 1 diabetes.
  17. Before and after surgery, severe infections, severe trauma.
  18. Patients with edema
  19. Subject had renal impairment(eGFR < 60 mL/min/1.73 m²)
  20. Subject who is a pregnant or nursing woman
  21. Subject had genetic dysfunctions like galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  22. Subjects who were deemed inappropriate to participate in the study by the investigator

Sites / Locations

  • Chonbuk National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Sequence 1

Sequence 2

Arm Description

Period 1: Reference drug(CKD-501, D745) Period 2: Test drug(CKD-398)

Period 1: Test drug(CKD-398) Period 2: Reference drug(CKD-501, D745)

Outcomes

Primary Outcome Measures

AUCt of CKD-398
Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.
Cmax of CKD-398
The maximum concentration observed of CKD-344 over blood sampling time.

Secondary Outcome Measures

AUCinf of CKD-398
Area under the concentration-time curve from zero up to ∞
Tmax of CKD-398
Time to maximum plasma concentration
T1/2 of CKD-398
Terminal elimination half-life
CL/F of CKD-398
Apparent Clearance
Vd/F of CKD-398
Apparent volume of distribution

Full Information

First Posted
April 28, 2021
Last Updated
August 24, 2021
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT04869800
Brief Title
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
Official Title
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-398 in Healthy Volunteers Under Fasting Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
May 27, 2021 (Actual)
Primary Completion Date
June 7, 2021 (Actual)
Study Completion Date
June 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
Detailed Description
A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-398 in healthy volunteers under fasting conditions

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Period 1: Reference drug(CKD-501, D745) Period 2: Test drug(CKD-398)
Arm Title
Sequence 2
Arm Type
Experimental
Arm Description
Period 1: Test drug(CKD-398) Period 2: Reference drug(CKD-501, D745)
Intervention Type
Drug
Intervention Name(s)
CKD-398
Intervention Description
Test Drug
Intervention Type
Drug
Intervention Name(s)
CKD-501, D745
Intervention Description
Reference Drug
Primary Outcome Measure Information:
Title
AUCt of CKD-398
Description
Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Title
Cmax of CKD-398
Description
The maximum concentration observed of CKD-344 over blood sampling time.
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Secondary Outcome Measure Information:
Title
AUCinf of CKD-398
Description
Area under the concentration-time curve from zero up to ∞
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Title
Tmax of CKD-398
Description
Time to maximum plasma concentration
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Title
T1/2 of CKD-398
Description
Terminal elimination half-life
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Title
CL/F of CKD-398
Description
Apparent Clearance
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Title
Vd/F of CKD-398
Description
Apparent volume of distribution
Time Frame
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
54 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adults age≥19 years and age<55 years at the time of screening Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg * BMI = Weight(kg)/ Height(m)2 Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital signs, ECG etc. performed at screening Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion Individuals with the ability and willingness to participate the entire study period Exclusion Criteria: Individuals with a medical evidence or a history (excluding a dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune diseases. Individuals with a medical history of gastrointestinal disease (e.g., gullet disease such as esophageal achalasia and esophagostenosis and Crohn's disease) or operations (excluding simple appendectomy, herniotomy or tooth extraction) that may affect drug absorption. Individuals with the following laboratory test results at screening: • ALT or AST > 2x the upper limit of the normal range History of regular alcohol consumption exceeding 210 g/week within the 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g) Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within the 6 months prior to the first dose of this study Following vital signs results at screening - Sitting systolic blood pressure ≥ 140 mmHg or < 90 mmHg and/or sitting diastolic blood pressure ≥90 mmHg or <60 mmHg Individuals with a medical history of significant alcohol or drug abuse within one year prior to the screening Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s) Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s) Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s) Individuals with severe acute/chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product(s) administration, or may interfere with the interpretation of study results Individuals with hypersensitivity to investigational products or the investigational products ingredients or dihydropyridine drugs Subject had severe heart failure(NYHA class 1, 2, 3, 4) Patients with hepatopathy Patients with diabetic ketogenic acidosis, diabetic comas and ex-coma, type 1 diabetes. Before and after surgery, severe infections, severe trauma. Patients with edema Subject had renal impairment(eGFR < 60 mL/min/1.73 m²) Subject who is a pregnant or nursing woman Subject had genetic dysfunctions like galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption Subjects who were deemed inappropriate to participate in the study by the investigator
Facility Information:
Facility Name
Chonbuk National University Hospital
City
Jeonju
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

We'll reach out to this number within 24 hrs